Daewoong Pharmaceutical participated in the IMCAS Asia 2019 to introduce the excellence of NABOTA

BALI,Indonesia and SEOUL,South Korea,July 9,2019 -- Daewoong Pharmaceutical Co.,Ltd,a world-leading botulinum toxin manufacturer in Korea,announced its participation in IMCAS Asia 2019 held in Bali,Indonesia July 5~7,2019 to introduce the excellence of NABOTA® (Prabotulinumtoxin A).

Daewoong Pharmaceutical Co.,Ltd in IMCAS Asia 2019

The 13th year of IMCAS (International Master Course on Aging Science) Asia is one of the topinternational conferencesfor plastic surgery,dermatology and aesthetic science. This year,around 85 corporate participants and 2,200 physicians had the opportunity to participate in the event.

Daewoong hosted an exhibition boothand a stand-alone symposium to present theexcellence of NABOTA and meaning ofFDA approval as the first 900 kDa botulinum toxin after Botox. Dr. Hema Sundaram,a US dermatologist who participatedin the global clinical trial andone of the faculty members of IMCAS Asia,had theopportunity to speakabout a massive global studythat involvedover 2,100 subjects in the US,EU,and Canada.

Dr. Hema Sundaram said,"Every physician wants to treat their patients with a trustable drug product. Botulinum toxin drug product manufactured by Daewoong Pharmaceutical had successfully proved its excellent efficacy and safety through FDA approval based on the fact that its non-inferiority results to Botox in all aspects of wrinkle improvement and stability in large-scale global clinical trials."

Alongside the exhibition,the NABOTA Aesthetic Forum (NAF in Bali) was held by Daewoong Pharmaceutical to invite more than 30 dermatologists and aesthetic surgeons from 6 different countries. This forum wasprepared by Daewoong Pharmaceutical for the5th straight year to share the opportunity to explore and update the new techniques and trends in the field.

With regards of first botulinum toxin clinical study in Vietnam,Dr. Pham Xuan Hung said,"In comparison study with NABOTA versus Botox,we have confirmed non-inferiority result to Botox,and it was an opportunity to confirm the excellent efficacy and safety of NABOTA from the Vietnamese as well."

"ThroughoutIMCAS Asia 2019,we have had a good opportunity to prove the excellence of NABOTA to global physicians. Based on NABOTA's proven excellence in quality and manufacturing process,we expect the significant increase of overseas sales and will continuously promote NABOTA's excellence and strengthen its position as a global brand," said Seongsoo Park,Executive Director of NABOTA Business Department in Daewoong Pharmaceutical.

Photo - /20190709/2518038-1